heart

This human trial is designed to evaluate the safety and efficacy of  Cardio3 BioSciences second generation stem cell therapy in patients with heart failure. The first patient was treated in March 2009.

BIOTRONIK, the pioneer in wireless remote monitoring technology for patients with cardiac devices, announced an agreement regarding a partnership with Belgian biotechnology company Cardio3 BioSciences in their C-Cure stem cell clinical trial.

Participants in the trial will receive an implantable cardioverter defibrillator (ICD) with Home Monitoring. These devices ensure optimal standard of care for patients with severe cardiac conditions.

Both the companies are looking forward to further progressing the trial which for the first time will evaluate in patients whether cardiopoietic cells, the active ingredient of C-Cure, can be used to re-generate heart muscle damaged by infarction.

It would be a two-phase, multi-center trial, where 240 patients suffering from ischemic cardiomyopathy at 35 sites in eleven countries will be treated with C-Cure.

C-Cure stem cell therapy C-Cure is a second generation cell therapy for the treatment of heart failure that involves taking a patients own stem cells from bone marrow and through a proprietary culturing technology generating differentiated cardiopoietic cells which can regenerate damaged heart muscle.

According to Dr Christian Homsy, CEO of Cardio3 BioSciences, they are very much delighted to be partnered with BIOTRONIK to provide ICD technology for the C-Cure trial.

In developing the stem cell technologies Cardio3 is driven by a desire to provide the best possible quality of treatment to patients with heart disease and this is carried through in choosing partners and suppliers for our trial. They believe that by working with BIOTRONIK they are giving patients access to the highest quality monitoring technology.

Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.

Source: Pharmacy Choice